Señales en vivo de HCM.L | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 11:35):

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally...

Stats
Volumen de hoy	17 687.00
Volumen promedio	87 291.00
Capitalización de mercado	2.70B
EPS	£0 ( 2024-02-27 )
Próxima fecha de ganancias	( £0 ) 2024-07-29
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-77.50
ATR14	£2.42 (0.78%)

Volumen Correlación

Largo: 0.02 (neutral)

Corto: -1.00 (very strong negative)

Signal:(51.295) Neutral

Hutchison China MediTech Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Hutchison China MediTech Correlación - Moneda/Commodity

-0.05
( neutral )

-0.18
( neutral )

0.27
( neutral )

-0.21
( neutral )

0.42
( neutral )

0.46
( neutral )

Hutchison China MediTech Finanzas

Annual	2023
Ingresos:	£838.00M
Beneficio Bruto:	£453.55M (54.12 %)
EPS:	£0.120

FY	2023
Ingresos:	£838.00M
Beneficio Bruto:	£453.55M (54.12 %)
EPS:	£0.120

FY	2022
Ingresos:	£426.41M
Beneficio Bruto:	£115.31M (27.04 %)
EPS:	£-0.520

FY	2021
Ingresos:	£356.13M
Beneficio Bruto:	£97.89M (27.49 %)
EPS:	£-0.250

Financial Reports:

No articles found.

Hutchison China MediTech

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.